Arrowhead Pharmaceuticals Shares jump over 23% Following Positive Data on RNAi Drug
BOSTON, November 27, 2025 – Shares of Arrowhead Pharmaceuticals surged more than 23% in trading today after teh company announced promising interim Phase 2 data for it’s investigational RNAi therapeutic, ARO-RNAi, targeting the transthyretin (TTR) protein.The positive results, presented at the 2025 American Heart Association Scientific Sessions, indicate meaningful reductions in serum TTR levels in patients with TTR amyloid cardiomyopathy.
The substantial increase in Arrowhead’s stock price reflects growing optimism surrounding ARO-RNAi as a potential treatment for this debilitating and often fatal disease. TTR amyloid cardiomyopathy occurs when misfolded TTR protein builds up in the heart, causing stiffness and ultimately heart failure.Current treatment options are limited, creating a significant unmet medical need and a possibly lucrative market for effective therapies. The data released today suggests ARO-RNAi could offer a substantial benefit to patients,driving investor enthusiasm.
according to the company’s release, interim data from the ongoing Phase 2 study demonstrated a dose-dependent reduction in serum TTR levels, with the highest dose tested achieving an 82% reduction at 28 days. Furthermore, the treatment appeared well-tolerated, with no treatment-related serious adverse events reported to date.
This positive progress arrives as the biotechnology sector continues to focus on RNA interference (RNAi) as a promising therapeutic modality. RNAi technology works by silencing specific genes, offering a targeted approach to treating diseases at thier source. Arrowhead Pharmaceuticals has been a key player in advancing RNAi therapeutics, and the ARO-RNAi data reinforces its position in the field.
Investors are closely watching the continued development of ARO-RNAi, with a Phase 3 trial anticipated to begin in the first half of 2026. The success of this trial will be crucial in determining the drug’s ultimate fate and its potential to become a standard of care for TTR amyloid cardiomyopathy.
While not included in a recent list of “10 best stocks” by Stock Advisor, which previously highlighted successful investments in Netflix (recommended December 17, 2004, with a 56,302% return as of November 24, 2025) and Nvidia (recommended April 15, 2005, with a 109,001% return as of November 24, 2025), today’s surge underscores the potential for significant returns in the biotech sector.stock Advisor boasts a total average return of 991%, significantly outperforming the S&P 500’s 192%.
Stock Advisor returns as of November 24, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
